Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas.

Metastatic Adult Soft Tissue Sarcoma Clinical Trial

Official title:

NGR016: Randomized Phase II Study Evaluating Two Doses of NGR-hTNF Administered Either as Single Agent or in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma (STS)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00484341
• Other study ID #: NGR016
• Secondary ID: 2010-018851-88
• Status: Completed
• Phase: Phase 2
• Start date: October 2010
• Est. completion date: May 2016

Study information

• Verified date: August 2018
• Source: MolMed S.p.A.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main objective of the trial is to document the preliminary antitumor activity of two doses of NGR-hTNF administered either alone or in combination with doxorubicin in locally advanced or metastatic soft-tissue sarcoma (STS) patients untreated or previously treated with one or more prior systemic regimen.

Description:

Considering the safety/toxicity profile of NGR-hTNF characterized by mild-to-moderate constitutional symptoms when given either every three weeks or weekly both at low (0.8 µg/m^2) and high dose (45 µg/m^2); the reversibility of these adverse events generally occurring only during the infusion time; the absence of overlapping toxicities with chemotherapeutic agents; and the safety and preliminary antitumor activity observed in phase Ib trial with doxorubicin, seems justified to evaluate in a randomized 4-arm phase II trial the preliminary antitumor activity of two doses of NGR-hTNF (0.8 µg/m^2 and 45 µg/m^2) administered weekly either alone or in combination with a standard dose of doxorubicin (60 mg/m^2 every three weeks).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 69
• Est. completion date: May 2016
• Est. primary completion date: May 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients = 18 years

• Histologically-proven, locally advanced, or metastatic STS (excluding extraosseus Ewing sarcoma)

• Patients not amenable to surgery, radiotherapy, or combined-modality therapy with curative intent

• Patients untreated or previously treated with one or more systemic regimen

• ECOG Performance status 0-2 (Appendix A)

• At least one untreated (not previously irradiated) target lesion that could be measured in one dimension, according to RECIST criteria

• A life expectancy of 12 weeks or more

• Adequate baseline bone marrow, hepatic and renal function, defined as follows:

• Neutrophils > 1.5 x 109/L and platelets > 100 x 109/L

• Bilirubin < 1.5 x ULN

• AST and/or ALT < 2.5 x ULN in absence of liver metastasis or < 5 x ULN in presence of liver metastasis

• Serum creatinine < 1.5 x ULN

• Creatinine clearance (estimated according to Cockcroft-Gault formula) = 50 ml/min

• Patients may have had prior treatment providing the following conditions are met before treatment start:

• Surgery and radiation therapy: wash-out period of 14 days

• Systemic therapy: wash-out period of 21 days

• Patients must give written informed consent

Exclusion Criteria:

• Patients may not receive any other investigational agents while on study

• Patients with myocardial infarction within the last six (6) months, unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication

• LVEF < 55% (only for patients candidate for doxorubicin treatment)

• Uncontrolled hypertension

• Prolonged QTc interval (congenital or acquired) > 450 ms

• History or evidence upon physical examination of CNS disease unless adequately treated (e.g., primary brain tumor, any brain metastasis, seizure not controlled with standard medical therapy) or history of stroke

• Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol

• Known hypersensitivity/allergic reaction or contraindications to human albumin preparations or to any of the excipients

• Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol

• Pregnancy or lactation. Patients - both males and females - with reproductive potential (i.e. menopausal for less than 1-year and not surgically sterilized) must practice effective contraceptive measures throughout the study. Women of child-bearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration

Related Conditions & MeSH terms

• Metastatic Adult Soft Tissue Sarcoma
• Sarcoma

Intervention

Drug:
• low-dose NGR-hTNF
NGR-hTNF: 0.8 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
• high-dose NGR-hTNF
NGR-hTNF: 45 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
• Doxorubicin
Doxorubicin: 60 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion) on day 1 every 3 weeks for a maximum of 6 cycles or until cumulative dose of 550 mg/m²

Locations

Country	Name	City	State
France	Centre Leon Berard	Lyon
France	Institut de Cancérologie Gustave Roussy	Villejuif
Italy	Istituto Ortopedico Rizzoli	Bologna
Italy	Fondazione IRCCS Istituto Nazionale dei Tumori di Milano	Milan
Italy	IRCCS Policlinico S. Matteo	Pavia
Italy	Università Campus Bio-Medico	Rome
United Kingdom	Clatterbridge Centre for Oncology	Bebington	Wirral

Sponsors (1)

Lead Sponsor	Collaborator
MolMed S.p.A.

Countries where clinical trial is conducted

France,  Italy,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-Free Survival (PFS)	Defined as the time from the date of randomization until disease progression, or death	every 6-12 weeks
Secondary	Safety and Toxicity according to NCI-CTCAE criteria (version 4.02)	To evaluate safety and toxicity profile related to NGR-hTNF	during the study
Secondary	Duration of Disease Control	Measured from the date of randomization until disease progression, or death due to any cause	every 6-12 weeks
Secondary	Overall survival (OS)	Defined as the time from the date of randomization until the date of death due to any cause or the last date the patient was known to be alive	every 6-12 weeks
Secondary	Response rate	Measured both according to RECIST criteria and by FDG-PET	every 6-12 weeks
Secondary	Tumor response	Evaluated by a centralized review of changes in tumor density on CT scan and/or perfusion MRI	every 6-12 weeks